GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lonza Group Ltd (OTCPK:LZAGF) » Definitions » EV-to-Revenue

LZAGF (Lonza Group) EV-to-Revenue : 6.13 (As of Dec. 14, 2024)


View and export this data going back to . Start your Free Trial

What is Lonza Group EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Lonza Group's enterprise value is $46,768 Mil. Lonza Group's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $7,628 Mil. Therefore, Lonza Group's EV-to-Revenue for today is 6.13.

The historical rank and industry rank for Lonza Group's EV-to-Revenue or its related term are showing as below:

LZAGF' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.87   Med: 5.37   Max: 13.64
Current: 6.13

During the past 13 years, the highest EV-to-Revenue of Lonza Group was 13.64. The lowest was 1.87. And the median was 5.37.

LZAGF's EV-to-Revenue is ranked worse than
71.43% of 217 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.01 vs LZAGF: 6.13

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-12-14), Lonza Group's stock price is $603.15. Lonza Group's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $105.29. Therefore, Lonza Group's PS Ratio for today is 5.73.


Lonza Group EV-to-Revenue Historical Data

The historical data trend for Lonza Group's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lonza Group EV-to-Revenue Chart

Lonza Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.03 10.12 10.38 5.48 4.02

Lonza Group Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 5.48 - 4.02 -

Competitive Comparison of Lonza Group's EV-to-Revenue

For the Diagnostics & Research subindustry, Lonza Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lonza Group's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lonza Group's EV-to-Revenue falls into.



Lonza Group EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Lonza Group's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=46767.987/7628.137
=6.13

Lonza Group's current Enterprise Value is $46,768 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lonza Group's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $7,628 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lonza Group  (OTCPK:LZAGF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Lonza Group's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=603.15/105.285
=5.73

Lonza Group's share price for today is $603.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2024 was $105.29.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lonza Group EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lonza Group's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lonza Group Business Description

Address
Muenchensteinerstrasse 38, Basel, CHE, CH-4002
Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.